Stock PAR PAR DRUGS AND CHEMICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Par Drugs and Chemicals Limited

Equities

PAR

INE04LG01015

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:40:31 2024-05-21 EDT 		5-day change 1st Jan Change
252.8 INR -3.44% Intraday chart for Par Drugs and Chemicals Limited +0.90% +17.22%
05-09 Par Drugs and Chemicals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
02-16 Par Drugs and Chemicals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: March 2020 2021 2022 2023
Capitalization 1 193.8 761.7 1,966 1,723
Enterprise Value (EV) 1 180.1 633.2 1,804 1,500
P/E ratio 4.07 x 6.56 x 21.3 x 15.2 x
Yield 7.94% - 0.78% -
Capitalization / Revenue 0.35 x 1.25 x 2.62 x 1.8 x
EV / Revenue 0.32 x 1.04 x 2.4 x 1.57 x
EV / EBITDA 1.91 x 3.95 x 11.1 x 8.24 x
EV / FCF 3.78 x 12.5 x 52.7 x 35.3 x
FCF Yield 26.5% 7.98% 1.9% 2.83%
Price to Book 0.48 x 1.46 x 3.28 x 2.42 x
Nbr of stocks (in thousands) 12,305 12,305 12,305 12,305
Reference price 2 15.75 61.90 159.8 140.0
Announcement Date 20-06-15 21-08-24 22-07-28 23-08-17
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 423.8 463.2 558.5 607.5 750.7 957.5
EBITDA 1 79.82 82.14 94.49 160.1 162.5 182.1
EBIT 1 48.46 51.77 66.87 131.9 129.7 149.7
Operating Margin 11.44% 11.18% 11.97% 21.72% 17.28% 15.64%
Earnings before Tax (EBT) 1 25.53 32.92 59.92 147.3 127 150.8
Net income 1 14.95 25.11 47.65 116.1 92.13 113.3
Net margin 3.53% 5.42% 8.53% 19.11% 12.27% 11.84%
EPS 2 2.769 2.800 3.873 9.435 7.488 9.210
Free Cash Flow 1 14.11 51.11 47.71 50.55 34.24 42.52
FCF margin 3.33% 11.03% 8.54% 8.32% 4.56% 4.44%
FCF Conversion (EBITDA) 17.68% 62.21% 50.49% 31.57% 21.06% 23.36%
FCF Conversion (Net income) 94.37% 203.52% 100.12% 43.54% 37.16% 37.52%
Dividend per Share - - 1.250 - 1.250 -
Announcement Date 19-03-31 19-04-10 20-06-15 21-08-24 22-07-28 23-08-17
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 231 116 - - - -
Net Cash position 1 - - 13.7 128 162 222
Leverage (Debt/EBITDA) 2.889 x 1.406 x - - - -
Free Cash Flow 1 14.1 51.1 47.7 50.6 34.2 42.5
ROE (net income / shareholders' equity) 7.49% 10% 13.7% 25% 16.4% 17.3%
ROA (Net income/ Total Assets) 5.51% 6.15% 7.5% 12.1% 10.5% 11.2%
Assets 1 271.5 408 634.9 961 881 1,015
Book Value Per Share 2 27.70 32.40 33.00 42.40 48.70 57.90
Cash Flow per Share 2 0.1200 0.0300 6.000 17.20 13.20 18.10
Capex 1 6.39 3.43 15.6 50.5 32 76.3
Capex / Sales 1.51% 0.74% 2.79% 8.31% 4.27% 7.97%
Announcement Date 19-03-31 19-04-10 20-06-15 21-08-24 22-07-28 23-08-17
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PAR DRUGS AND CHEMICALS LIMITED Stock Par Drugs and Chemicals Limited
+17.22% 38.55M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.31% 705B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.37% 583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.58% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.23% 332B
ABBVIE INC. Stock AbbVie Inc.
+5.16% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.11% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-3.72% 210B
NOVARTIS AG Stock Novartis AG
+10.47% 209B
AMGEN INC. Stock Amgen Inc.
+8.60% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PAR Stock
  4. Financials Par Drugs and Chemicals Limited
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW